Clinical trial NCT05772013: Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Official title: Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations (OPACE): A Double Blind Adaptive Design Pragmatic Phase IV Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
Azithromycin
Chemoprophylaxis
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: University of Aberdeen
name: NHS Greater Glasgow and Clyde
name: University of East Anglia
name: Nottingham City Hospital
name: Swansea University
name: Newcastle University
name: University of Cambridge
name: NHS Sunderland Clinical Commissioning Group
name: Liverpool School of Tropical Medicine
name: Royal Brompton & Harefield NHS Foundation Trust
name: University College London Hospitals
name: Liverpool Heart and Chest Hospital NHS Foundation Trust
name: Imperial College London
name: Red Graphic
name: Eramol (UK) Ltd.
name: WGK Clinical Services Ltd.
name: Sealed Envelope Ltd.
name: National Institute for Health Research, United Kingdom
First posted: 2023-03-16
Enrollment: 1311
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: People living with chronic obstructive pulmonary disease (COPD) may experience worsening of symptoms such as shortness of breath, cough and wheezing in addition to changes that may be expected for having COPD. The worsening of symptoms is called exacerbations or flare-ups and can be debilitating and frightening, requiring additional treatment, often with azithromycin. This is an antibiotic medicine that also has anti-inflammatory properties. It is prescribed as long-term prevention to reduce the risk of flare-ups. Some people may be affected by side effects from azithromycin. Antibiotic resistance is another concern, especially when using azithromycin for prevention rather than to treat active infection.

It is currently unclear as to whether people should be advised to stop taking azithromycin once COPD has stabilised, or to stop it over the summer when fewer flare-ups happen. It is also not known if azithromycin is more effective in some people or more likely to cause side effects in others. Given these uncertainties, it is challenging to know how best to use azithromycin in managing COPD. Azithromycin is a valuable antibiotic, and should be prescribed where it has benefit but avoid unnecessary side effects and reduce the chances of bacteria becoming resistant to it.

The purpose of this trial is to be able to gain results to answer these questions, and to establish the effects of stopping azithromycin in people whose COPD has stabilised, who have been taking it for at least 3 months. This trial will compare continuing azithromycin with stopping it completely, or stopping over the summer only, continuing over the winter. The investigators will compare the effects of these three treatments in the trial on flare-ups, symptoms and quality of life, and find out what factors may affect how individual participants respond to them.

Detailed description: Background: Prophylactic azithromycin is recommended as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in people with COPD at high risk of exacerbations. In clinical practice, there is much uncertainty in how to optimally use this valuable treatment in managing COPD. It is unknown whether azithromycin is effective beyond one-year of treatment; what happens when azithromycin is discontinued following a period of use; or temporarily discontinued over the summer when there are fewer exacerbations. Whether there are differences in treatment responsiveness between subgroups of people with COPD is also uncertain.

Aim: To evaluate the benefits and risks of complete or seasonal discontinuation of azithromycin chemoprophylaxis vs continued treatment in people with stable COPD at high risk of exacerbations and assess effects in participant subgroups.

Methods: Design: A randomised double-blinded, non-inferiority, adaptive-design pragmatic trial of 3 parallel arms (complete discontinuation, vs seasonal discontinuation vs continued azithromycin as standard of care), to test the strategy of discontinuation of prophylactic azithromycin in participants with stable COPD at high risk of exacerbations. Internal pilot to evaluate recruitment will run for 9 months from first participant first visit (FPFV).

Randomisation allocation will be 1:1:1. Adaptive design means a treatment arm can be dropped if futile at interim analysis, but remaining arms continue.

Setting: General Practitioner (GP) practices, specialist community clinics, hospitals.

Target population: Stable COPD participants prescribed azithromycin ≥3 months to reduce risk of COPD exacerbations.

Interventions assessed: Complete discontinuation of azithromycin (matched placebo), seasonal discontinuation (azithromycin October-March, matched placebo April-September), continued azithromycin (standard of care).

Trial duration and procedures: Median follow up will be 24 months. Participants will have up to 3 visits - baseline, 12 months, 24 months/end of trial, which may coincide with standard of care visits and be in-person or remote depending on participant's individual preference. Telephone follow-up will be conducted at 1 week, 3 months, 6 months, and 18 months. All participants will have active follow up until study end, even if primary endpoint met. If participants have 3 or more exacerbations/year they will be advised to stop their trial medication. Participants may restart regular azithromycin prescription after stopping trial medication if advised by their GP/specialist. Secondary outcomes will be collected over the entire trial period and therefore may include evaluation both on and off trial medication.

Outcome measures:

Primary endpoint: Time to first exacerbation (TTFE) necessitating additional treatment with antibiotics and/or corticosteroids.

Key secondary endpoints (collected over entire trial)

1. Number/rate and severity of exacerbations, length of exacerbation-free status
2. Health related quality of life measured by change in the EuroQol-5 dimension
3. Symptoms (COPD assessment tool (CAT) score and cough)
4. Side effects
5. Mortality
6. Cost effectiveness from National Health Service (NHS) perspective.

Sample size: 1311 participants (437 per arm). Assuming a median TTFE of 150 days and non-inferiority threshold of 30 days shorter, equates to the threshold on the hazard ratio scale of 1.25. Sample size is based on 90 percent power for two non-inferiority comparisons (seasonal and placebo compared with continuous as standard treatment), at 2.7 percent significance using a Cox proportional hazards model. Pre-specified factors for subgroup analysis include exacerbation history, forced expiratory volume at one second (FEV1 percentage) predicted, current/ex-smoking status, COPD Assessment Tool (CAT) score, age, blood eosinophils.

Conclusion:

This pragmatic, real world trial aims to answer the uncertainties regarding prophylactic azithromycin use in COPD.

Eligibility criteria: Inclusion Criteria:

* Be able and willing to provide informed consent.
* Have an established clinical diagnosis of COPD and be receiving prophylactic azithromycin for ≥ (at least) 3 months to reduce COPD exacerbations.
* Have a self-reported smoking history of ≥ (at least) 10 pack years.
* Be aged \>= 40 years.
* Have clinically stable COPD, i.e. no COPD exacerbation for at least 6 weeks.

Exclusion Criteria:

* Known hypersensitivity to any of the trial drugs or excipients.
* Current breast feeding, pregnancy or planned pregnancy during the trial.
* Any medical history or clinically relevant abnormality that makes participant ineligible for inclusion because of a safety concern relating to continuing or discontinuing azithromycin or other considerations.
* Known immunodeficiency requiring immunoglobulin/specific antibody therapy.
* Azithromycin prophylaxis prescribed for non-COPD condition.
* Active participation in COPD Clinical Trial of an Investigational Medicinal Product (CTIMP).

Electrocardiograms (ECGs) will not be a trial assessment nor entry requirement.

Primary outcomes:
measure: COPD exacerbation
timeFrame: Throughout the entire trial follow-up of 24 months
Secondary outcomes:
measure: Number and rate of exacerbations
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Exacerbation-free period
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Treatment for respiratory indication
timeFrame: Throughout the entire trial follow-up of 24 months
measure: CAT Score
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Cough visual analogue scale (VAS) score
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Health status
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Mortality
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Healthcare utilisation
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Adverse events of special interest (AESI) and Serious Adverse Reactions (SARs)
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Sputum culture results
timeFrame: Throughout the entire trial follow-up of 24 months
measure: Adherence to trial medication
timeFrame: Throughout the entire trial follow-up of 24 months
Other outcomes:
Locations:
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospital NHS Trust, Addenbrookes Hospital
Study officials:
affiliation: University of Cambridge & University of Cambridge NHS Foundation Trust
name: Ian B Wilkinson
role: STUDY_DIRECTOR
References: